128502-56-7

Basic information

• Product Name: L-7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
• Synonyms: L-7-HYDROXY-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBOXYLIC ACID;L-7-HYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID;L-7-HYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID DIHYDRATE;L-1,2,3,4-TETRAHYDRO-7-HYDROXYISOQUINOLINE-3-CARBOXYLIC ACID DIHYDRATE;L-1,2,3,4-TETRAHYDRO-7-HYDROXYISOQUINOLINE-3-CARBOXYLIC ACID HYDRATE;H-TIC(7-HYDROXY)-OH 2H2O;H-TIC(7-OH)-OH 2H2O;H-TIC(H-HYDROXY)-OH 2H2O
• CAS NO: 128502-56-7
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.2
• Product Categories: pharmacetical;Amino Acids
• Mol File: 128502-56-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 273-275 °C
• Boiling Point: 329.41°C (rough estimate)
• Flash Point: 229.751 °C
• Appearance: off-white to beige or grey crystalline powder
• Density: 1.2307 (rough estimate)
• Vapor Pressure: 4.06E-09mmHg at 25°C
• Refractive Index: 1.5300 (estimate)
• Storage Temp.: 2-8°C
• PKA: 2.19±0.20(Predicted)
• CAS DataBase Reference: L-7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: L-7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid(128502-56-7)
• EPA Substance Registry System: L-7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid(128502-56-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25-26
• Hazardous Substances Data: 128502-56-7(Hazardous Substances Data)

Usage

Chemical Properties

off-white to beige or grey crystalline powder

Uses

L-7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid is a possible histone deacetylases (HDACs) inhibitor. It is used in the design of boronic acid-based autotaxin inhibitors.

InChI:InChI=1/C10H11NO3/c12-8-2-1-6-4-9(10(13)14)11-5-7(6)3-8/h1-3,9,11-12H,4-5H2,(H,13,14)

Upstream product

• 109-87-5 Dimethoxymethane 
• 60-18-4 L-tyrosine 
• 300-39-0 3,5-diiodo-l-tyrosine 
• 142335-40-8 (S)-1,2,3,4-Tetrahydro-7-hydroxy-6,8-diiodoisoquinoline-3-carboxylic acid 

Downstream Products

• 201413-66-3 methyl (3S)-N-benzyloxycarbonyl-1,2,3,4-tetrahydro-7-hydroxyisoquinoline-3-carboxylate 
• 1312201-56-1 (S)-2-(4-fluorobenzyl)-7-hydroxy-10,10a-dihydroimidazo-[1,5-b]isoquinoline-1,3(2H,5H)-dione 
• 1312201-58-3 (S)-(4-(((2-(4-fluorobenzyl)-1,3-dioxo-1,2,3,5,10,10a-hexahydroimidazo[1,5-b]isoquinolin-7-yl)oxy)methyl)phenyl)boronic acid 
• 142335-42-0 (3S)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid 

Relevant articles and documents

Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity

The prominent role of IAPs in controlling cell death and their overexpression in a variety of cancers has prompted the development of IAP antagonists as potential antitumor therapies. We describe the identification of a series of heterodimeric antagonists with highly potent antiproliferative activities in cIAP- and XIAP-dependent cell lines. Compounds 15 and 17 further demonstrate curative efficacy in human melanoma and lung cancer xenograft models and are promising candidates for advanced studies.

PROTEOLYSIS-TARGETING CHIMERAS

The present disclosure provides compounds of the formula (I) wherein these compounds contain a ligand which binds to one or more target proteins such as CDK4 or CDK6 and a ligand which binds to the machinery associated with the ubiquitinating protein machinery. Also provided herein are methods of using these compounds in compositions or methods of treating patients with these compounds for the treatment of a disease or disorders such as cancer.

IAP ANTAGONISTS

There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.